UAMY Q2: Breakeven Profit Masks Inventory Bloat; DLA Ramp Still Unproven

What happened

UAMY’s Q2 2026 revenue rose to $7.9 million from $6.8 million in Q1, and the company eked out net income of $0.1 million after an $11.3 million loss last quarter. Antimony pounds sold excluding DLA grew 26% sequentially, and zeolite revenue more than doubled year-over-year, indicating some operational momentum. However, antimony inventory surged 178% from year-end and working capital doubled to $70 million, signaling that production is still far outpacing revenue conversion. Management pointed to accelerating DLA shipments in the second half, but provided no revenue breakdown or volume figures for the defense contract. The update leaves the core question unchanged: whether Thompson Falls can convert inventory into accepted sales before working-capital strain forces another capital raise.

Implication

Investors should view the slight net profit cautiously, as it came despite a 178% surge in antimony inventory and a doubling of working capital to $70 million, which suggests revenue recognition is not keeping pace with production. The lack of quantified DLA revenue is a red flag, given that the market’s valuation depends on defense shipments ramping sharply. The stock’s current $7.30 level may not hold if the next quarterly filing fails to show DLA revenue above $10 million and inventory declining meaningfully. Until then, the risk-reward remains unattractive because working-capital consumption raises the odds of another equity issuance. The WAIT rating stands, and the attractive entry near $5.50 remains distant.

Thesis delta

The Q2 numbers shift the balance of evidence toward the bear case: inventory ballooning relative to sales indicates conversion is lagging, and the tiny net income offers no buffer for operational setbacks. The bull thesis now requires a dramatic second-half acceleration in DLA shipments to absorb inventory, just as the industrial contract renewal looms. Until that acceleration materializes in reported revenue, the stock’s premium valuation is harder to justify.